Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
344
Completed, industry sponsors, Kidney and urology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed344
344 trials
Showing 1 to 25, recently updated first.
- To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisPivotal-lookingCompleted
Akebia TherapeuticsIndustry
NCT06901505 · 353 participants · Start Jul 24, 2025 · Primary completion Aug 12, 2026
Drug: Erythropoiesis-Stimulating Agent (ESA); Vadadustat · For: Anemia of Chronic Kidney Disease
Sites: Montgomery, Alabama; Hartford, Connecticut; Middlebury, Connecticut · 18 sites in all
- Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04578834 · 517 participants · Start Jan 25, 2021 · Primary completion Sep 19, 2025
Drug: Placebo; LNP023 · For: IgA Nephropathy
Sites: Glendale, Arizona; Phoenix, Arizona; Los Angeles, California · 177 sites in all
- A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 DiabetesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05901831 · 242 participants · Start Feb 26, 2024 · Primary completion Aug 20, 2025
Drug: Finerenone · For: Chronic Kidney Disease; Type 1 Diabetes Mellitus
Sites: Surprise, Arizona; Stanford, California; Vallejo, California · 79 sites in all
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyPivotal-lookingCompleted
Travere Therapeutics, Inc.Industry
NCT03762850 · 406 participants · Start Dec 11, 2018 · Primary completion Aug 7, 2023
Drug: sparsentan; irbesartan and 1 more · For: Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Homewood, Alabama; Glendale, California · 162 sites in all
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05021835 · 6,385 participants · Start Aug 30, 2021 · Primary completion Jun 9, 2026
Drug: Ziltivekimab B; Ziltivekimab C and 2 more · For: Cardiovascular Risk; Chronic Kidney Disease; Inflammation
Sites: Birmingham, Alabama; Montgomery, Alabama; Glendale, Arizona · 1,073 sites in all
- A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)Pivotal-lookingCompleted
Nanogen Pharmaceutical Biotechnology Joint Stock CompanyIndustry
NCT05585645 · 214 participants · Start Aug 8, 2019 · Primary completion Nov 23, 2022
Drug: Stimus (NNG-DEPO) · For: Anemia; Chronic Kidney Disease Requiring Chronic Dialysis
Sites: Ho Chi Minh City, Vietnam
- To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe PruritusPivotal-lookingCompleted
Galderma R&DIndustry
NCT05075408 · 258 participants · Start Mar 18, 2022 · Primary completion Jan 4, 2024
Drug: Nemolizumab; Nemolizumab and 1 more · For: Chronic Kidney Disease Associated Moderate to Severe Pruritus
Sites: Bakersfield, California; Glendale, California; La Palma, California · 64 sites in all
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05803421 · 2,749 participants · Start Apr 3, 2023 · Primary completion Mar 16, 2026
Drug: Orforglipron; Insulin Glargine · For: Type 2 Diabetes; Obesity; Overweight or Obesity and 3 more
Sites: Daphne, Alabama; Mobile, Alabama; Pelham, Alabama · 358 sites in all
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Pivotal-lookingCompleted
Travere Therapeutics, Inc.Industry
NCT03493685 · 371 participants · Start Apr 17, 2018 · Primary completion Mar 20, 2023
Drug: sparsentan; Irbesartan · For: Focal Segmental Glomerulosclerosis
Sites: Mesa, Arizona; Phoenix, Arizona; Los Angeles, California · 226 sites in all
- Trial Evaluating the Efficacy and Safety of Patiromer in Chinese SubjectsPivotal-lookingCompleted
Vifor Fresenius Medical Care Renal PharmaIndustry
NCT05136664 · 262 participants · Start Feb 10, 2022 · Primary completion Nov 18, 2025
Drug: Patiromer Powder for Oral Suspension (Part A); Placebo (Part B) and 1 more · For: Hyperkalemia; Renal Insufficiency, Chronic
Sites: Hefei, China; Beijing, China; Lanzhou, China · 28 sites in all
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT03439137 · 323 participants · Start Feb 14, 2018 · Primary completion Dec 12, 2018
Drug: MT-6548; Darbepoetin alfa and 2 more · For: Anemia; Hemodialysis Dependent Chronic Kidney Disease
Sites: Aichi, Japan; Chiba, Japan; Fukui, Japan · 28 sites in all
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT03329196 · 304 participants · Start Oct 30, 2017 · Primary completion Jan 8, 2019
Drug: MT-6548; Darbepoetin alfa · For: Anemia; Non-dialysis Dependent Chronic Kidney Disease
Sites: Aichi, Japan; Chiba, Japan; Fukui, Japan · 31 sites in all
- Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT03402386 · 42 participants · Start Jan 3, 2018 · Primary completion Nov 22, 2018
Drug: MT-6548 · For: Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease
Sites: Aichi, Japan; Chiba, Japan; Fukuoka, Japan · 17 sites in all
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT03461146 · 24 participants · Start Mar 5, 2018 · Primary completion Dec 3, 2018
Drug: MT-6548 · For: Anemia; Hemodialysis Dependent Chronic Kidney Disease
Sites: Aichi, Japan; Chiba, Japan; Fukushima, Japan · 16 sites in all
- A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05047263 · 1,584 participants · Start Sep 21, 2021 · Primary completion Dec 31, 2025
Drug: Finerenone (BAY94-8862); Placebo · For: Non-diabetic Chronic Kidney Disease
Sites: Huntsville, Alabama; Chula Vista, California; El Centro, California · 326 sites in all
- A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04865770 · 106 participants · Start Apr 28, 2021 · Primary completion Nov 21, 2024
Drug: Semaglutide; Placebo (Semaglutide) · For: Diabetes Mellitus, Type 2; Chronic Kidney Disease
Sites: Tucson, Arizona; Los Angeles, California; National City, California · 49 sites in all
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)Pivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00500682 · 1,020 participants · Start Jul 2007 · Primary completion Oct 2011
Drug: Placebo; AST-120 · For: Chronic Kidney Disease
Sites: Phoenix, Arizona; Little Rock, Arkansas; Alhambra, California · 105 sites in all
- Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00772382 · 116 participants · Start Dec 2008 · Primary completion Aug 2010
Drug: MCI-196 · For: Chronic Kidney Disease; Dialysis; Hyperphosphatemia
Sites: Los Angeles, California; Orange, California; Tarzana, California · 21 sites in all
- A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With HyperphosphatemiaPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00416520 · 336 participants · Start Jun 2007 · Primary completion Nov 2009
Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®); Placebo and 1 more · For: Chronic Kidney Disease; Hyperphosphatemia
Sites: Adelaide, Australia; Nedlands, Australia; Parkville, Australia · 68 sites in all
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)Pivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00501046 · 1,015 participants · Start Jul 2007 · Primary completion Oct 2011
Drug: Placebo; AST-120 · For: Chronic Kidney Disease
Sites: Tuscaloosa, Alabama; Hot Springs, Arkansas; Bakersfield, California · 106 sites in all
- A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With HyperphosphatemiaPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00506441 · 245 participants · Start Sep 2007 · Primary completion Sep 2009
Drug: MCI-196; Placebo · For: Chronic Kidney Disease; Dialysis; Hyperphosphatemia
Sites: Glendale, Arizona; Tempe, Arizona; Hot Springs, Arkansas · 39 sites in all
- A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and DyslipidaemiaPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00542386 · 642 participants · Start Dec 2007 · Primary completion Nov 2009
Drug: MCI-196; Placebo · For: Chronic Kidney Disease; Dialysis; Hyperphosphatemia and 1 more
Sites: Ajka, Hungary; Baja, Hungary; Budapest, Hungary · 73 sites in all
- Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on DialysisPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00858637 · 260 participants · Start Mar 2009 · Primary completion Mar 2010
Drug: MCI-196; Placebo of Simvastatin and 2 more · For: Chronic Kidney Disease
Sites: Brest, Belarus; Grodno, Belarus; Homyel, Belarus · 39 sites in all
- A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00542815 · 632 participants · Start Nov 2007 · Primary completion Aug 2010
Drug: MCI-196; Another Phosphate binder (Sevelamer) · For: Chronic Kidney Disease; Dialysis; Hyperphosphatemia
Sites: Graz, Austria; Frýdek-Místek, Czechia; Hradec Králové, Czechia · 115 sites in all
- Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic HyperplasiaPivotal-lookingCompleted
EMSIndustry
NCT04185441 · 295 participants · Start Mar 14, 2021 · Primary completion Oct 10, 2023
Drug: Tanzânia association; Omnic Ocas · For: Erectile Dysfunction; Benign Prostatic Hyperplasia
Sites: Campinas, Brazil
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.